Can Eli Lilly defend obesity-drug profits as competition and pricing pressure increase?
已發布報告原文節錄 · 原文語言: 英文
The evidence supports a narrower conclusion; the original investment thesis remains unconfirmed. Evidence review: The revenue and demand evidence supports volume-led growth and lower realized prices, but Mounjaro is reported as a diabetes product as well as part of Lilly’s broader incretin franchise. Product-specific volume and access data are not disclosed, so the obesity-specific conclusion is broader than the evi…報告部分資料來源